Related Experiment Video
Updated: Jun 27, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Effects of levosimendan on left atrial functions in patients with ischemic heart failure
Hamza Duygu1, Sanem Nalbantgil, Filiz Ozerkan
1Department of Cardiology, Ege University Medical Faculty, Izmir, Turkey. hamzakard@yahoo.com
Insights
Levosimendan significantly improved left atrial (LA) function in patients with heart failure (HF) compared to dobutamine. This drug enhanced active emptying fraction, passive emptying fraction, and reservoir function, offering better outcomes for HF patients.
Area of Science:
- Cardiology
- Pharmacology
- Physiology
Background:
- Left ventricular (LV) dysfunction in heart failure (HF) leads to decreased left atrial (LA) contribution to LV filling.
- LA dysfunction exacerbates reduced LV filling in HF patients.
Purpose of the Study:
- To investigate the effects of levosimendan on LA function in patients with acute decompensated HF.
- To compare the efficacy of levosimendan versus dobutamine in improving LA function.
Main Methods:
- A randomized study of 60 patients with acute decompensated HF and LV ejection fraction (LVEF) < 40%.
- Patients received either levosimendan (n=30) or dobutamine (n=30).
- LA function parameters including active emptying fraction (AEF), passive emptying fraction (PEF), and reservoir fraction (RF) were measured before and after 24 hours of treatment.
Main Results:
- Levosimendan significantly reduced LA volumes and improved AEF, PEF, and RF.
- Improvements in PEF and RF were significantly greater with levosimendan compared to dobutamine.
- Positive correlations were observed between PEF, Em, and negative correlations between PEF/AEF and E/Em in the levosimendan group.
Conclusions:
- Levosimendan demonstrates superior efficacy in improving LA function compared to dobutamine in patients with decompensated HF.
- The findings suggest levosimendan as a potential therapeutic option for enhancing cardiac function in HF.
Background:
With further progression of left ventricular (LV) dysfunction, the left atrial (LA) contribution to LV filling gradually decreases, and LA dysfunction deteriorates the decreased LV filling in patients with heart failure (HF).
Hypothesis:
This study sought to investigate the effects of levosimendan on LA function in patients with HF.
Methods:
A total of 60 patients having acute decompensated HF with ischemic cardiomyopathy and LV ejection fraction (LVEF) < 40% were included in the study. Patients were randomized to levosimendan (n = 30) or to dobutamine (n = 30). Before and 24 h after treatment, LVEF, mitral inflow peak E and A wave velocity, E/A ratio, mitral lateral annulus peak Em wave velocity, E/Em ratio, LA volumes, and from the LA volumes the active emptying fraction (AEF), passive emptying fraction (PEF), and reservoir fraction (RF) were measured.
Results:
All LA volumes were significantly reduced after levosimendan administration, but in the dobutamine group only minimal volume (Vmin) was reduced. Although AEF increased in both groups, the improvement of AEF was greater in the levosimendan group than in the dobutamine group (14% +/- 9% versus 2% +/- 1%, p = 0.001). The PEF (12% +/- 8% versus 21% +/- 6%, p = 0.04) and RF (23% +/- 4% versus 38% +/- 3%, p = 0.001) significantly increased after levosimendan administration, whereas these parameters did not change after dobutamine. In patients receiving levosimendan, there was a significant, positive correlation between PEF and Em (r = 0.475, p = 0.008), and there were significant negative correlations between PEF and E/Em (r = - 0.491, p = 0.006), and AEF and E/Em (r = - 0.654, p = 0.001).
Conclusions:
Left atrial functions respond better to levosimendan than to dobutamine in decompensated HF.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Heart Failure Drugs: β-Blockers
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies